MAPK3 and metastatic melanoma: Treatment of MeWo and B16F10 metastatic melanoma cell lines with 11a-1 effectively blocks SHP2-mediated ERK1/2 and AKT activation and attenuates cell viability, anchorage-independent growth, and migration.